These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a report of 12 patients].
    Author: Sun YQ, Xu LP, Liu DH, Zhang XH, Han W, Chen H, Wang FR, Wang JZ, Wang Y, Chen YH, Liu KY, Huang XJ.
    Journal: Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):113-6. PubMed ID: 23611216.
    Abstract:
    OBJECTIVE: To retrospectively review the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelomonocytic leukemia (CMML). METHODS: The engraftment, graft versus host disease (GVHD), infection, relapse and survival of 12 CMML patients received allo-HSCT were observed. The clinical outcome of allo-HSCT for CMML was analyzed. RESULTS: Twelve (7 males and 5 females) CMML patients with a median age of 39 years old received allo-HSCT including 7 from HLA-matched sibling and 5 from haploidentical related donors. All 12 patients achieved engraftment. The median time of neutrophil engraftment and platelet engraftment were 15 (11 - 20) days and 13 (11 - 18) days, respectively. 4 patients occurred acute GVHD, and 3 occurred chronic GVHD. After the median follow-up of 17.5 months (12 - 32 months), the overall survival, disease free survival and relapse rate were 66.7%, 66.7%, and 16.7%, respectively. CONCLUSION: Allo-HSCT can improve the survival of patients with CMML, and is a effective therapy for CMML.
    [Abstract] [Full Text] [Related] [New Search]